Press releaseGlobe Newswire
Maia Biotechnology
MAIA · NYSE American
$1.12+$0.05 (+4.67%)TodayMarket closed ·
Prev close $1.07
Latest news
- Press releaseGlobe Newswire
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
- News
MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung Cancer
- Press releaseGlobe Newswire
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
- Press releaseGlobe Newswire
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
- Press releaseGlobe Newswire
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
- Press releaseGlobe Newswire
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
- Press releaseGlobe Newswire
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
- Press releaseGlobe Newswire
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
- Press releaseGlobe Newswire
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
- Press releaseGlobe Newswire
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
- NewsAvi Kapoor
Crude Oil Surges Over 6%; Target Profit Tops Views
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Dow Dips 900 Points; Best Buy Posts Upbeat Earnings
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releasePRNewswire
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
- Press releasePRNewswire
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
- Press releasePRNewswire
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
- Press releaseGlobe Newswire
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
- Press releaseBusiness Wire
MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
- Press releaseBusiness Wire
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
- Press releaseBusiness Wire
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
- Press releaseBusiness Wire
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress
- Press releaseBusiness Wire
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
- Press releaseBusiness Wire
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
- Press releaseBusiness Wire
MAIA Biotechnology to Present at BIO International Convention 2025
- Press releaseBusiness Wire
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
- Press releaseBusiness Wire
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
- Press releaseBusiness Wire
MAIA Biotechnology Announces Private Placement of Approximately $669,500
- Press releaseBusiness Wire
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
- Press releaseBusiness Wire
MAIA Biotechnology Announces Director Participation in Recent Private Placement
- Press releaseBusiness Wire
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement
- Press releaseBusiness Wire
MAIA Biotechnology Announces $1.08 Million Private Placement
- Press releaseBusiness Wire
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
- Press releaseBusiness Wire
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
- Press releaseBusiness Wire
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
- Press releaseBusiness Wire
MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO
- Press releaseBusiness Wire
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
- Press releaseBusiness Wire
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
- NewsAvi Kapoor
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.